David Seaburg

Chief Executive Officer

David Seaburg spent the past 25 years of his career at Cowen, Inc., a leading healthcare franchise in equities research, sales and investment banking. He was Managing Director, Head of Sales Trading and a member of the Cowen’s Equity Operating Committee, where he cultivated and led teams operating across multiple disciplines and specialties, leveraging human capital to drive the organization’s success. Over the course of his tenure, he interacted with thousands of healthcare investors and corporate management teams. Mr. Seaburg was recently the CEO of a publicly traded biotechnology organization, PolarityTE MD, Inc., and was formerly an analyst on CNBC’s Fast Money, where he provided regular on-air market commentary for the network. David is a co-founder of Stella Diagnostics and serves on the Company's Board of Directors.

Joe Abdo, PhD

Co-inventor / Co-founder

Joe Abdo has over a decade of experience in molecular oncology research, and R&D and business development in both private and public biotechnology organizations. Dr. Abdo has won several awards for his research and has published over a dozen articles and a text book in the fields of molecular oncology, proteomics, genomics, immunotherapy and gastrointestinal diseases, placing advancements in patient care at the forefront of his work. He earned a PhD in Clinical and Translational Science from Creighton University School of Medicine where he investigated biochemical mechanisms of Barrett's-related esophageal adenocarcinoma. He also received a Master’s degree in Biotechnology from Georgetown University School of Medicine where he researched genomic and proteomic expression abnormalities in patients with gastro-intestinal diseases. Most recently, he was the Chief Executive Officer of Stella Diagnostics and was the Senior Director of Clinical and Translational Science at PolarityTE, MD Inc.

Fred Zaino


Fred Zaino founded Keystone Capital Partners in 2019. Recognizing a shift in investment strategy and the growing need for micro-cap, small-cap, and mid-cap public and private companies to access reliable capital sources, Mr. Zaino established Keystone in an effort to help overlooked and underfunded companies reach their goals. Recognizing that the best returns are often generated from the strongest partnerships, Keystone invests in building long-term, mutually beneficial relationships with strong management teams to help them meet and exceed their business objectives. As Chief Investment Officer, Mr. Zaino is responsible for identifying public and private equity investments through bottom-up fundamental analysis. While sector-agnostic, industries of focus include biotech, real estate and consumer products. Fred and Keystone Capital Partners made the founding investment into Stella Diagnostics to build and validate the assay via corporate and clinical partnerships.